Arthur J. Shannon | Valeant Pharmaceuticals International, Inc. |
Joseph C. Papa | Valeant Pharmaceuticals International, Inc. |
Paul S. Herendeen | Valeant Pharmaceuticals International, Inc. |
Mark McKenna | Salix Pharmaceuticals |
Annabel Eva Samimy | Stifel, Nicolaus & Co., Inc. |
Umer Raffat | Evercore Group LLC |
Greg Fraser | Deutsche Bank |
Chris Z. Neyor | JPMorgan Securities LLC |
David R. Risinger | Morgan Stanley & Co. LLC |
Jennifer Kim | Cantor Fitzgerald Securities |
David A. Amsellem | Piper Jaffray & Co. |
Ladies and gentlemen, thank you for standing by and welcome to Valeant first quarter 2018 earnings call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. I will now turn the call over to Mr. Art Shannon, Senior Vice President, Investor Relations.